Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

BACKGROUND: A prospective, randomised phase II study demonstrated clinical benefit of axitinib dose titration in a subset of treatment-naïve patients treated with axitinib for metastatic renal cell carcinoma. This analysis evaluated patient baseline characteristics that may impact overall survival (...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Yoshihiko, Uemura, Hirotsugu, Oya, Mototsugu, Shinohara, Nobuo, Habuchi, Tomonori, Fujii, Yosuke, Kamei, Yoichi, Umeyama, Yoshiko, Bair, Angel H., Rini, Brian I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322336/
https://www.ncbi.nlm.nih.gov/pubmed/30616534
http://dx.doi.org/10.1186/s12885-018-5224-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322336/
https://www.ncbi.nlm.nih.gov/pubmed/30616534
http://dx.doi.org/10.1186/s12885-018-5224-6

Ejemplares similares